These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 10801821

  • 1. Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation.
    Wang W, Nagashima M, Schneider M, Morser J, Nesheim M.
    J Biol Chem; 2000 Jul 28; 275(30):22942-7. PubMed ID: 10801821
    [Abstract] [Full Text] [Related]

  • 2. Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C.
    Kokame K, Zheng X, Sadler JE.
    J Biol Chem; 1998 May 15; 273(20):12135-9. PubMed ID: 9575159
    [Abstract] [Full Text] [Related]

  • 3. Amino acid residues in the P6-P'3 region of thrombin-activable fibrinolysis inhibitor (TAFI) do not determine the thrombomodulin dependence of TAFI activation.
    Schneider M, Nagashima M, Knappe S, Zhao L, Morser J, Nesheim M.
    J Biol Chem; 2002 Mar 22; 277(12):9944-51. PubMed ID: 11786552
    [Abstract] [Full Text] [Related]

  • 4. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains.
    Hall SW, Nagashima M, Zhao L, Morser J, Leung LL.
    J Biol Chem; 1999 Sep 03; 274(36):25510-6. PubMed ID: 10464282
    [Abstract] [Full Text] [Related]

  • 5. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor.
    Bajzar L, Nesheim M, Morser J, Tracy PB.
    J Biol Chem; 1998 Jan 30; 273(5):2792-8. PubMed ID: 9446587
    [Abstract] [Full Text] [Related]

  • 6. The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.
    Wu C, Kim PY, Manuel R, Seto M, Whitlow M, Nagashima M, Morser J, Gils A, Declerck P, Nesheim ME.
    J Biol Chem; 2009 Mar 13; 284(11):7059-67. PubMed ID: 19074424
    [Abstract] [Full Text] [Related]

  • 7. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential.
    Wu C, Stafford AR, Fredenburgh JC, Weitz JI, Gils A, Declerck PJ, Kim PY.
    Thromb Haemost; 2017 Jul 26; 117(8):1509-1517. PubMed ID: 28640323
    [Abstract] [Full Text] [Related]

  • 8. Activation of protein C and thrombin activable fibrinolysis inhibitor on cultured human endothelial cells.
    Wu C, Kim PY, Swystun LL, Liaw PC, Weitz JI.
    J Thromb Haemost; 2016 Feb 26; 14(2):366-74. PubMed ID: 26663133
    [Abstract] [Full Text] [Related]

  • 9. Alanine-scanning mutagenesis of the epidermal growth factor-like domains of human thrombomodulin identifies critical residues for its cofactor activity.
    Nagashima M, Lundh E, Leonard JC, Morser J, Parkinson JF.
    J Biol Chem; 1993 Feb 05; 268(4):2888-92. PubMed ID: 8381415
    [Abstract] [Full Text] [Related]

  • 10. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
    Incampo F, Carrieri C, Semeraro N, Colucci M.
    Thromb Res; 2014 Nov 05; 134(5):1110-6. PubMed ID: 25193406
    [Abstract] [Full Text] [Related]

  • 11. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
    Boffa MB, Wang W, Bajzar L, Nesheim ME.
    J Biol Chem; 1998 Jan 23; 273(4):2127-35. PubMed ID: 9442053
    [Abstract] [Full Text] [Related]

  • 12. Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin.
    Marar TT, Boffa MB.
    J Thromb Haemost; 2016 Apr 23; 14(4):772-83. PubMed ID: 26816270
    [Abstract] [Full Text] [Related]

  • 13. Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI.
    Roussel JC, Moran CJ, Salvaris EJ, Nandurkar HH, d'Apice AJ, Cowan PJ.
    Am J Transplant; 2008 Jun 23; 8(6):1101-12. PubMed ID: 18444940
    [Abstract] [Full Text] [Related]

  • 14. VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.
    van Moorsel MVA, Poolen GC, Koekman CA, Verhoef S, de Maat S, Barendrecht A, van Kleef ND, Meijers JCM, Schiffelers RM, Maas C, Urbanus RT.
    J Thromb Haemost; 2022 May 23; 20(5):1213-1222. PubMed ID: 35170225
    [Abstract] [Full Text] [Related]

  • 15. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.
    Plug T, Marquart JA, Marx PF, Meijers JC.
    J Thromb Haemost; 2015 Nov 23; 13(11):2093-101. PubMed ID: 26341360
    [Abstract] [Full Text] [Related]

  • 16. A case of thrombomodulin mutation causing defective thrombin binding with absence of protein C and TAFI activation.
    Okada M, Tominaga N, Honda G, Nishioka J, Akita N, Hayashi T, Suzuki K, Moriuchi H.
    Blood Adv; 2020 Jun 23; 4(12):2631-2639. PubMed ID: 32556284
    [Abstract] [Full Text] [Related]

  • 17. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
    Mosnier LO.
    J Biol Chem; 2011 Jan 07; 286(1):502-10. PubMed ID: 21041299
    [Abstract] [Full Text] [Related]

  • 18. Structure-function studies of the epidermal growth factor domains of human thrombomodulin.
    Parkinson JF, Nagashima M, Kuhn I, Leonard J, Morser J.
    Biochem Biophys Res Commun; 1992 Jun 15; 185(2):567-76. PubMed ID: 1319140
    [Abstract] [Full Text] [Related]

  • 19. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
    Bajzar L, Nesheim ME, Tracy PB.
    Blood; 1996 Sep 15; 88(6):2093-100. PubMed ID: 8822928
    [Abstract] [Full Text] [Related]

  • 20. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage.
    Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JC, Bouma BN.
    J Biol Chem; 2000 Apr 28; 275(17):12410-5. PubMed ID: 10777524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.